The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The Indian government has floated a scheme for the promotion of research and innovation in the pharmaceutical and medical technology sector, with an aim to reduce the country’s dependence on imports of products such as orphan drugs. 15 September 2023
Florida, USA-based clinical-stage biotech First Wave BioPharma has entered an agreement with French pharma major Sanofi to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications. 15 September 2023
A new US biotech, Arialys Therapeutics, which is pioneering new therapeutics for autoimmune neuropsychiatry, has announced the closing of $58 million in seed financing. 15 September 2023
US health technology assessor the Institute for Clinical and Economic Review ICER) today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of atidarsagene autotemcel (“arsa-cel”), from USA and UK-based Orchard Therapeutics, for metachromatic leukodystrophy (MLD). 14 September 2023
A US Food and Drug Administration advisory panel on Wednesday backed the expanded use of Alnylam Pharmaceuticals' gene silencing drug to treat a type of heart disease associated with a rare organ-damaging disorder. 14 September 2023
AlveoGene, a UK-based company focused on transforming rare respiratory disease outcomes using inhaled gene therapy has announced its launch. 14 September 2023
A company founded by Flagship Pioneering, Generate Biomedicines, has raised over a quarter of a billion dollars in a series C financing round. 14 September 2023
The HOPE trial - together with a clinical mechanism of action study - strengthens the case for Lundbeck's Lu AG09222, as additional data highlights the anti-pituitary adenylate cyclase-activating polypeptide (PACAP) monoclonal antibody (mAb) as a potential preventive treatment for migraine. 14 September 2023
US clinical-stage immune-oncology firm Harpoon Therapeutics yesterday revealed that AbbVie has decided not exercise its exclusive license option in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. 14 September 2023
US biopharma firm Eiger BioPharmaceuticals saw its shares plummet more than 40% to $0.41, after it announced its decision to discontinue the Phase III LIMT-2c study of peginterferon lambda in patients with chronic hepatitis delta (CHD). 14 September 2023
French immuno-oncology specialist OSE Immunotherapeutics has announced that the results from its Phase III trial (ATALANTE-1) for Tedopi (OSE: 2101) have been published in Annals of Oncology. 14 September 2023
Stock in New Jersey, USA-based Rocket Pharmaceuticals shot up around 40% on Wednesday, following good news on the financing and regulatory fronts. 14 September 2023
In France, a recently-founded biotech focused on the tumor microenvironment has agreed terms for a licensing and co-development program with SATT Nord. 14 September 2023
Shares of London-listed blood disease specialist Hemogenyx Pharmaceuticals were up more than 9% at 1.80 pence, after it revealed in a stock exchange filing a positive development for its investigational product. 14 September 2023
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final draft guidance that recommends US pharma giant Pfizer’s Vydura (rimegepant) as an option for the acute treatment of migraine. 14 September 2023
Taiwan-based BRIM Biotechnology today announced that 22,500 shares have been issued at a premium of NT$65 (~US$2.03), raising a total of NT$1.4625 billion (~US$45.8 million). 13 September 2023
US biotech Moderna has spent much of the last couple of years banging the drum about the potential of its mRNA platform beyond producing the COVID-19 vaccine that brought the company multi-billion dollar sales and global acclaim. 13 September 2023